To assess the impact of activity restriction (AR) on the incidence of preterm birth in women treated for preterm labor testing negative for fetal fibronectin (fFN).
INTRODUCTION
Ongoing care of a woman following an episode of preterm labor may include the recommendation of decreased activity. Activity restriction (AR) is a common intervention used in an effort to prolong gestation in women experiencing signs and symptoms of preterm labor. In the United States, antepartum bed rest is prescribed for more than 700,000 women per year. 1 The results of many published studies have been inconsistent in terms of the impact of AR on the rate of preterm birth. [2] [3] [4] [5] [6] Indeed, extended bed rest may do harm by increasing a woman's chance of thromboembolism, and may decrease maternal weight gain and be associated with an increased risk of fetal growth restriction. 1, 7 Fetal fibronectin (fFN) has emerged as a primary biochemical marker useful in identifying those patients at increased risk of preterm delivery. [8] [9] [10] A number of clinical studies have been conducted to determine the association of cervicovaginal fFN and the risk of preterm delivery. Reported sensitivities, specificities, and positive and negative predictive values have varied considerably based on the chosen study outcome and population examined. Several studies have reported that the fFN assay has a high negative predictive value for delivery within a defined period. [9] [10] [11] [12] However, a patient presenting with symptoms of preterm labor, but with a negative fFN assay, can prove to be a clinical challenge.
The purpose of this study was to examine the impact of AR on the preterm birth rate among women experiencing preterm labor with a negative fFN.
MATERIALS AND METHODS
This study was a prospective, randomized controlled trial conducted between November 1997 and September 2000. The study protocol was approved by an Investigational Review Board (IRB) at each of the four participating tertiary hospitals in the southwestern United States. Women presenting with clinical criteria of preterm labor and tocolyzed with intravenous (i.v.) magnesium sulfate (MgSO 4 ) were screened with fFN as part of the assessment process immediately following admission. Those women testing fFN negative were screened for the following study inclusion criteria: >14 years of age, intact membranes, documented uterine contractions of Z6/hour at admission, 23 0/7-33 6/7 weeks' gestation, r3 cm cervical dilatation at the time of fFN testing. Gestational age was established by last normal menstrual period (LNMP) in concert with either a first trimester or early second trimester ultrasound. Ultrasound measurements established the EDC in those cases where the first trimester ultrasound differed from the LNMP by more than 7 or 14 days in the second trimester ultrasound. Patients with moderate to gross vaginal bleeding, cervical cerclage, complaints of leaking with confirmed rupture membranes, fetal or maternal conditions requiring immediate delivery or prolonged hospitalization that would necessitate bed rest (e.g., nonreassuring fetal testing, preeclampsia, chorioamnionitis), and/or major congenital anomalies were excluded.
After stabilization with MgSO 4 , those patients meeting inclusion criteria and agreeing to participate were consented with an IRB approved consent form. Patients were randomized using a computer-generated randomization schedule to either AR group or no activity restriction (NAR group). Study coordinators utilized an 800 number where a third party not involved with study operations opened an opaque, sealed randomization envelope and reported group assignment to the study coordinator at the respective site. Correct group assignment was validated by the study monitor at the termination of the study. Caregivers were not blinded to group assignment.
A cervicovaginal specimen was collected for fFN immunoassay as per the manufacturer's guidelines (Adeza Biomedical, Sylmar, CA, USA) for the FDA-approved indication of preterm labor. Study participants had a urine culture and sensitivity, as well as cervicovaginal cultures for Group B streptococcus and other organisms, as clinically indicated. Fern and nitrazine tests were utilized to confirm rupture of the membranes. Digital exam of the cervix including dilatation, effacement/length, station, position, and consistency was obtained following collection of the fFN immunoassay.
All patients received i.v. magnesium sulfate (MgSO 4 ) for tocolysis to treat the acute episode of preterm labor. The initial dose of MgSO 4 was a 4-6 g bolus over 20 minutes, followed by 2-4 g/hour until preterm labor was arrested as evidenced by uterine quiescence and arrest of cervical dilatation as per clinical determination of the attending physician. Magnesium levels were collected every 6-8 hours, with levels between 5 and 7 mg/dl considered in the acceptable range.
All patients were managed with AR prior to hospital discharge. AR consisted of bed rest with the exception of bathroom and showering privileges. Among those patients who were randomized to the AR group, these ARs were modified at hospital discharge to include being able to travel to their physician appointments. All subjects received verbal and written instruction regarding detection of signs and symptoms of preterm labor. The patients randomized to the NAR group were instructed to resume normal activities, including home and work responsibilities. Upon hospital discharge, all study participants continued care with their primary care obstetrician on a weekly basis times two, then every 2 weeks, and as needed thereafter. Patients were called weekly by study nurses and questioned regarding compliance with assigned activity group.
Study participants with recurrent preterm labor were readmitted for evaluation. Those with a clinical presentation of Z6 contractions/hour and cervical advancement of Z1 cm or Z25% effacement from the previous exam were defined as treatment failures, that is, refractory to assigned protocol. For the recurrent episode of preterm labor, treatment failures received the same clinical protocol as administered at study entry, including i.v. MgSO 4 . Following stabilization, subjects resumed their original group assignment (AR or NAR).
Participants were discontinued from the study at 37 0/7 weeks' gestation, or delivery, whichever occurred first. The attending physician could withdraw the subject from the study at any time if an alternative course of treatment was deemed in the best interest of the study participant and/or her fetus.
Data for the two study groups were compared using independent Student's t-test, Fisher's Exact test and Mann-Whitney U-test statistics. Two-sided p-values <0.05 were considered statistically significant. A sample size calculation was performed for the outcome of pregnancy prolongation. It was determined that we would need to enroll 1625 patients to show a clinically meaningful difference of 7±20 days between the study groups. Observed power was calculated for select study end points, with Z80% (b ¼ 0.20) considered sufficient to exclude Type II error. While physician withdrawal of patients (8) and drop-outs (3) occurred in both groups, such events occurred at similar rates (p ¼ 0.115). Therefore, all analyses were conducted according to original study group assignment, that is, intent-to-treat.
The primary study end point was pregnancy prolongation from initiation of the study protocol to delivery. Secondary outcomes analyzed included preterm birth rate, low and very low birth-weight (LBW, VLBW), and neonatal intensive care unit (NICU) days.
RESULTS
A total of 882 women were screened for the study. Of these, 246 women were eligible to participate. Of the 246 eligible, 73 (30%) women met inclusion criteria, consented, and were enrolled. A total of 36 women were randomized to the AR group and 37 women were randomized to the NAR group. Primary reasons for study exclusion were cervical dilatation >3 cm or data not available, <6 contractions/hour at hospital admission, maternal/fetal condition necessitating prolonged hospitalization, gestational age <23 0/7 or >33 6/7 weeks, or ruptured membranes.
There were no demographic differences between the two study groups at enrollment. Table 1 describes the study population, which, overall, represented women 24 years of age, with the majority having at least a high school education, married or living with a partner.
Obstetrical risk factors and clinical presentation at study entry for the overall population are presented in Table 2 . Nearly a third (29%) of the overall study group reported a history of preterm birth. There were few twin gestations in this study population with two of 36 in the AR group and four of 37 in the NAR group (NS). There were no differences between the groups in terms of gestational age at study entry, cervical dilatation or uterine contractions per hour. Overall, these women presented to the hospital for evaluation of preterm labor signs and/or symptoms on average at 30.8 weeks' gestation with uterine activity averaging 16 contractions/hour per hospital tocodynamometry. Cervical dilatation by digital examination at study entry was similar in both groups.
A subgroup analysis comparing women who subsequently delivered preterm was also performed. Clinical characteristics at study enrollment were similar between the groups (data not shown) with the exception of cervical effacement, which was nearly statistically significant with 51% effacement in the AR group vs 29% effacement in the NAR group (p ¼ 0.056). In women who delivered preterm in the present study, 40% had a history of preterm birth as well.
All study participants were tocolyzed with i.v. MgSO 4 at study admission. Following the initial bolus, patients were maintained on Betamethasone was administered to enhance fetal lung maturity in 88.9% (32) of women in the AR group and 94.6% (35) of women in the NAR group (p ¼ 0.430). Antibiotics were administered for <5 days in 89% of the overall study population pending cultures for group B streptococcus. Antibiotics were continued if cultures were positive. No women in the AR group and 13.5% (five) of women in the NAR group received antibiotics Z5 days (p ¼ 0.024). In the AR group, two (5.6%) women received oral medications for maintenance tocolysis: one received ibuprofen and the other one received terbutaline and indomethacin. In the NAR group, seven (19%) women received oral maintenance tocolysis: five women received terbutaline and two women received nifedipine (p ¼ 0.152).
Hospitalization days following enrollment were minimal, although statistically significant between the groups with a mean of 1.5±1.3 days in the AR group and 3.0±4.3 in the NAR group (p ¼ 0.04). Five women in the AR group (13.9%) and four in the NAR group (10.8%) had subsequent hospital readmission for preterm labor and re-treatment with MgSO 4 (p ¼ 0.736).
No differences were found between the groups with regard to maternal and neonatal outcomes (Tables 3 and 4 ). In this highrisk study population testing fFN negative at study entry, 44.4% of women randomized to the AR group delivered preterm while 35.1% of those randomized to the NAR group delivered preterm. In the AR In this study population, no significant differences were found between the groups relative to neonatal outcomes (Table 4) . Almost one-fourth (22%) of the overall neonates in the study population were admitted to the NICU with a mean length of stay of 19 days in the AR group vs 4.7 days in the NAR group; 22 of 79 (28%) neonates were LBW. There was no perinatal mortality in the study population.
SIGNIFICANCE
Traditional interventions to prevent preterm birth include tocolytic administration, antibiotic therapy, outpatient contraction surveillance, and AR. Women with a negative fFN test are frequently regarded as normal with minimal subsequent risk for preterm birth. Nevertheless, these same patients are frequently counseled to reduce their activity, or even to observe bed rest, despite the lack of evidence to support that intervention. Consequently, we chose to study AR, recognizing that its justification is controversial, but relies on a presumed association between physical activity and uterine activity. The pathophysiologic support for this belief is constrained by the lack of understanding in mechanisms that operate to cause preterm labor, let alone preterm birth. The contrarian view suggests that bed rest may produce increases in physical and psychological complications. Recent evidence suggests that bed rest is associated with significant bone mineral density loss as measured by dual-energy X-ray absorptiometry in a longitudinal cohort being prospectively evaluated for trabecular and cortical bone loss. Promislow et al. 13 presented convincing evidence that bed rest was associated with the greatest reductions in bone mineral density when compared to other accepted risk factors such as nulliparity, calcium intake <2000 mg/day, and low weight gain. Decreased muscle mass, decreased lung capacity, and increased risk of thrombosis have also been reported in pregnant women prescribed bed rest.
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Psychological repercussions often ensue, including restlessness, boredom, depression, and frustration. The results of many published studies have been inconsistent in terms of the impact of AR on the rate of preterm birth. Luke et al. 3 found that the risk of preterm delivery increased among a cohort of working nurses. Conversely, Berkowitz et al. 4 reported no effect of employment, housework, or childcare on the risk of preterm birth. A recently published study by Misra et al. 14 reported that the odds of preterm delivery were increased for women who climb stairs more than 10 times per day and for women who engage in walking more than four times per week. In Cochrane Database review articles, bed rest for at-risk singleton and multiple gestation pregnancies did not prevent preterm birth. 5, 6 Previous reports have suggested that women testing negative for fFN are at minimal risk for subsequent preterm delivery within 14 days of specimen acquisition. [9] [10] [11] [12] It is generally accepted that <1% of pregnant women will deliver within 1 week after a negative test, <3% in 14 days, and <10-12% will experience a preterm delivery (<37 weeks gestation). In the present study, 9.6% of women treated for preterm labor testing negative for fFN delivered within 14 days. In contrast, we observed an overall preterm birth rate of 40%. This finding suggests that the risk for preterm delivery within 2 weeks while minimal is considerably higher than currently reported for patients presenting with preterm labor symptoms. This finding may in part be explained by the nature of our population, who were both high risk in terms of prior pregnancy outcome and patients who were symptomatic in the index pregnancy. The other explanation focuses on how these prior studies were conducted. Whether you consider the Lockwood et al. 8 pioneering work or the NICHD Preterm Prediction Study trial, 12 they both used a similar methodology in that fFN specimens were collected prospectively, but the results were not available to the clinicians and as a result did not influence the clinical management. Consequently, all of these patients with preterm labor were treated in accordance with each clinical sites accepted practice, both acutely and in follow-up. We speculate that the follow-up was most likely much more rigorous and the counseling much more comprehensive than current practice. It is our experience that a negative fFN almost relegates one to a virtual no-risk status and short-term follow-up is uncertain.
Our findings support the notion that symptomatic high-risk patients remain at significant risk for preterm delivery even when their fFN results are negative. This finding is potentially even more significant when you consider the minimal cervical dilatation of 1 cm at study entry. It is possible that our inclusion criteria were sufficiently rigorous (Z6 contractions/hour requiring parenteral tocolysis) such that we selected a patient population more likely to deliver prematurely. Indeed, our patients had frequent contractions (16/hour) and a high rate of prior preterm birth (29%).
While there was a significant difference in the utilization of prolonged antibiotics in the NAR group, there is no evidence to suggest that this difference had a significant impact on our outcome. Similarly, there may be some confounding effect in the relative disparity of oral tocolytic use and the length of antepartum hospitalization between the two groups. While most investigators do not believe that oral tocolytic agents have any definitive effect on clinical outcome, it remains unclear whether there is some synergistic effect when combining the use of antibiotics, tocolytic agents, and prolonged hospitalization.
In the present study of women who were treated for preterm labor in the setting of a negative fFN, we found no statistical difference in the incidence of preterm birth between patients with and without AR. Statistically significant differences in antepartum hospital days were noted between the groups. Women randomized to NAR had twice the number of antepartum hospital days than women in the AR group, and while not statistically significant, a greater number of women in the NAR group received oral maintenance tocolysis. This could possibly indicate that AR lessened maternal symptoms of preterm labor, although additional studies would be required to test this interaction.
In this study, we examined the efficacy of AR in women treated for preterm labor who tested negative for fFN at hospital admission. The small sample size and inability to definitively measure differences in maternal activity levels and compliance with the assigned group are weaknesses of the present study. When we began this study, we anticipated wide-spread acceptance of the study protocol by private physicians at the study sites and much more vigorous enrollment. Although the study subsequently was ended due to low enrollment, we feel that the clinical information collected remains relevant when taken within the proper context. While AR was not found to impact pregnancy outcome in this population of women treated for preterm labor testing negative for fFN, the observations that overall 3% of patients delivered within 7 days, 10% delivered within 14 days, and 40% delivered preterm are important findings. For many clinicians, the negative predictive value of fFN has become a mainstay of patient management. If our results are confirmed by larger prospective trials, we will have to rethink clinical management relative to an adjusted negative predictive value. Certainly, the value of fFN in the setting of a prior history of preterm delivery needs to be re-evaluated. Results of fFN testing, either positive or negative, must be placed into context based on the patients' entire historical and current clinical picture. Based on these data, it would be prudent for a physician caring for a patient following stabilized preterm labor to increase the level of outpatient surveillance including uterine activity assessment, weekly office visits, and cervical assessment as needed.
